Clinical Trial Update: Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients. [Phase 2]

View source ↗

Summary

Phase 2 trial update reports on safety and efficacy of olesoxime (TRO19622) in children and young adults with spinal muscular atrophy types II and non-ambulant …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy Type Ii
• Spinal Muscular Atrophy Type Iii Non-ambulant

Drugs mentioned

• Olesoxime (TRO19622)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III Non Ambulant | Phase 2 | Status: COMPLETED